Free Trial
→ A 3M Oz. Historical Gold Resource And A Market That Hasn't Caught Up (From Wall Street Logic) (Ad)tc pixel
NASDAQ:RLYB

Rallybio Q1 2026 Earnings Report

Rallybio logo
$15.90 -0.02 (-0.13%)
Closing price 06/15/2026 04:00 PM Eastern
Extended Trading
$15.90 +0.00 (+0.03%)
As of 06/15/2026 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Rallybio EPS Results

Actual EPS
-$1.46
Consensus EPS
-$1.20
Beat/Miss
Missed by -$0.26
One Year Ago EPS
N/A

Rallybio Revenue Results

Actual Revenue
$0.21 million
Expected Revenue
$0.21 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Rallybio Announcement Details

Quarter
Q1 2026
Date
5/13/2026
Time
Before Market Opens
Conference Call Date
Thursday, May 7, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Rallybio's next earnings date is estimated for Thursday, August 6, 2026, based on past reporting schedules.

Conference Call Resources

Rallybio Earnings Headlines

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
June 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260602266487/en/rallybio-investor-alert-kahn-swick-foti-llc-investigates-merger-of-rallybio-corporation---rlyb/
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?
June 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/rlyb-stock-hits-2-highs-162629816.html
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insiders and institutional holders have been sitting on positions for years and will exit the moment shares hit the market. Lance Ippolito has identified five stocks directly positioned to benefit from the SpaceX launch and the space investing wave it triggers, without the brutal IPO volatility. These picks carry none of the hype risk and all of the tailwind.tc pixel
June 16 at 1:00 AM  |  InvestPub (Ad)
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders
June 1, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260601190294/en/RLYB-Stock-Alert-Halper-Sadeh-LLC-is-Investigating-Whether-Rallybio-Corporation-is-Obtaining-a-Fair-Price-for-its-Shareholders/
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
June 1, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260531328050/en/rallybio-corporation-and-avenzo-therapeutics-announce-merger-agreement-to-advance-next-generation-oncology-therapies-and-215-million-concurrent-private-placement/
Rallybio Corporation
May 22, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/RLYB
See More Rallybio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rallybio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rallybio and other key companies, straight to your email.

About Rallybio

Rallybio (NASDAQ:RLYB) Therapeutics, Inc. (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency. Additional pipeline candidates target lysosomal storage disorders and severe skin fragility syndromes, underscoring the company’s commitment to a precision‐medicine approach. Each program has been selected based on compelling preclinical or early clinical data that suggest a clear path to regulatory milestones and commercialization.

Founded in 2018 and headquartered in New York City, Rallybio completed its initial public offering via a business combination in 2021. The company leverages strategic partnerships, external research collaborations and internal manufacturing capabilities to accelerate development timelines and maintain rigorous quality standards. While Rallybio’s primary operations are based in the United States, its clinical trial network spans North America, Europe and Asia Pacific, reflecting its objective to serve rare disease communities on a global scale.

Rallybio is led by a management team with extensive experience in rare disease research, drug development and regulatory strategy. The company aims to build on its scientific foundation by expanding its pipeline, advancing key assets toward commercialization and fostering collaborations that enhance access to therapies for underserved patient populations worldwide.

View Rallybio Profile
Earnings Tools